Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3764-3773

  Melinda, L Telli ^a   Kirsten, M Timms ^b   Julia, Reid ^b   Bryan, Hennessy ^c   Gordon, B Mills ^c   Kristin, C Jensen ^a   Zoltan, Szallasi ^d,e,f   William, T Barry ^f,g   Eric, P Winer ^f,g   Nadine, M Tung ^f,h   Steven, J Isakoff ^f,i   Paula, D Ryan ⁱ   April, Greene Colozzi ^g   Alexander, Gutin ^b   Zaina, Sangale ^b   Diana, Iliev ^b   Chris, Neff ^b   Victor, Abkevich ^b   Joshua, T Jones ^b   Jerry, S Lanchbury ^b   Anne Renee, Hartman ^b   Judy, E Garber ^f,g   James, M Ford ^a   Daniel, P Silver ^a,f,g   Andrea, L Richardson ^f,g,j,k   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Utah   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; INIPARIB; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM; TUMOR MARKER;

ADJUVANT THERAPY; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC PARAMETERS; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HOMOLOGOUS RECOMBINATION DEFICIENCY SCORE; HUMAN; HUMAN TISSUE; LARGE SCALE STATE TRANSITION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; TELOMERIC ALLELIC IMBALANCE; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ALLELIC IMBALANCE; CANCER STAGING; CLINICAL TRIAL; GENETICS; MORTALITY; MUTATION; ODDS RATIO; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; TELOMERE; TREATMENT OUTCOME;

ALLELIC IMBALANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; FEMALE; GENES, BRCA1; GENES, BRCA2; HOMOLOGOUS RECOMBINATION; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM STAGING; ODDS RATIO; PLATINUM; PROGNOSIS; TELOMERE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84980347772     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2477     Document Type: Article

References (31)

1. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
2. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007;26:2126-32.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
4. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11:5175-80.
5. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004;64:64-71.
6. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-32.
7. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 2010;107:16910-5.
8. Silver DP, Livingston DM. Mechanisms of BRCA1 tumor suppression. Cancer Discov 2012;2:679-84.
9. Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115:359-63.
10. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69:3589-96.
11. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 2010;70:7970-80.
12. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.
13. Ryan PD, Tung NM, Isakoff SJ, Golshan M, Richardson A, Corben AD, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. J Clin Oncol 2009;27:551.
14. Rugo H, Olopade O, DeMichele A, van 't Veer L, Buxton M, Hylton N, et al. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL. Cancer Res 2013;73(24 Suppl): Abstract S5-02.
15. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15:747-56.
16. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33:13-21.
17. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107:1776-82.
18. Birkbak NJ, Wang ZC, Kim J-Y, Eklund AC, Li Q, Tian R, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNAdamaging agents. Cancer Discov 2012;2:366-75.
19. Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, et al. Ploidy and large-scale genomic instability consistently identify basallike breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72:5454-62.
20. Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, et al. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 2014; 16:475.
21. Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res 2015;3:9.
22. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 2015;33:1895-901.
23. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28:3570-6.
24. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
25. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
26. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
27. Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet 2012;205:341-55.
28. Eggington JM, Bowles KR, Moyes K, Manley S, Esterling L, Sizemore S, et al. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 2014;86:229-37.
29. R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
30. Von Minckwitz G, Timms K, Untch M, Elkin EP, Fasching PA, Schneeweiss A, et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from Gepar-Sixto. J Clin Oncol 2015;33.
31. Telli ML, Audeh W, Jensen KC, Bose S, Timms K, Gutin A, et al. Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR. Abstract P5-06-01.